Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
Araujo CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Silva MSR, Yuki EFN, Pasoto SG, Pedrosa T, Kupa LVK, Zou G, Pereira RMR, Silva CA, Aikawa NE, Bonfa E. Araujo CSR, et al. Among authors: kupa lvk. Ann Rheum Dis. 2022 Jun;81(6):889-897. doi: 10.1136/annrheumdis-2021-221916. Epub 2022 Feb 22. Ann Rheum Dis. 2022. PMID: 35193873 Clinical Trial.
Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis.
Medeiros-Ribeiro AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, da Silva HC, Saad CGS, Yuki EFN, Pasoto SG, Araujo CSR, Nakai TL, Silva CA, Pedrosa T, Kupa LVK, Silva MSR, Balbi GGM, Kallas EG, Aikawa NE, Bonfa E. Medeiros-Ribeiro AC, et al. Among authors: kupa lvk. Ann Rheum Dis. 2022 May;81(5):710-719. doi: 10.1136/annrheumdis-2021-221735. Epub 2022 Feb 8. Ann Rheum Dis. 2022. PMID: 35135832
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.
Aikawa NE, Kupa LVK, Medeiros-Ribeiro AC, Saad CGS, Yuki EFN, Pasoto SG, Rojo PT, Pereira RMR, Shinjo SK, Sampaio-Barros PD, Andrade DCO, Halpern ASR, Fuller R, Souza FHC, Guedes LKN, Assad APL, Moraes JCB, Lopes MRU, Martins VAO, Betancourt L, Ribeiro CT, Sales LP, Bertoglio IM, Bonoldi VLN, Mello RLP, Balbi GGM, Sartori AMC, Antonangelo L, Silva CA, Bonfa E. Aikawa NE, et al. Among authors: kupa lvk. Ann Rheum Dis. 2022 Jul;81(7):1036-1043. doi: 10.1136/annrheumdis-2021-222096. Epub 2022 Mar 11. Ann Rheum Dis. 2022. PMID: 35277389
Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
Signorelli F, Balbi GGM, Aikawa NE, Silva CA, Kupa LVK, Medeiros-Ribeiro AC, Yuki EF, Pasoto SG, Saad CG, Borba EF, Seguro LPC, Pedrosa T, Oliveira VAA, Costa ALCS, Ribeiro CT, Santos REB, Andrade DCO, Bonfá E. Signorelli F, et al. Among authors: kupa lvk. Lupus. 2022 Jul;31(8):974-984. doi: 10.1177/09612033221102073. Epub 2022 May 20. Lupus. 2022. PMID: 35593174 Free PMC article.
Lupus nephritis-related issues during COVID-19 pandemic quarantine.
Pedrosa T, Kupa LVK, Aikawa NE, Pasoto SG, Bonfá E, Silva CA. Pedrosa T, et al. Among authors: kupa lvk. Lupus. 2020 Dec;29(14):1978-1980. doi: 10.1177/0961203320957098. Epub 2020 Sep 2. Lupus. 2020. PMID: 32878557 No abstract available.
24 results